Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Rhythm Biosciences Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Rhythm Biosciences hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.7%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-AU$0.034
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von RHY in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von RHY gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Rhythm Biosciences Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von RHY im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (RHY)	n/a
Untere 25 % des Marktes (AU)	2.7%
Markt Top 25 % (AU)	6.4%
Branchendurchschnitt (Healthcare)	2.7%
Analystenprognose in 3 Jahren (RHY)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von RHY im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von RHY im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von RHY, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da RHY keine Ausschüttungen gemeldet hat.

Rhythm Biosciences Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million.

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million.

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

New major risk - Share price stability

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New minor risk - Shareholder dilution

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

New minor risk - Financial data availability

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Executive Chairman recently bought AU$248k worth of stock

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited

Less than half of directors are independent

Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022

Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer

Executive Chairman recently sold AU$6.5m worth of stock

Executive Chairman exercised options to buy AU$459k worth of stock.

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers

Less than half of directors are independent

Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ®

Rhythm Biosciences Ltd Announces Executive Changes

Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding

Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7)

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Non-Executive Director David White has left the company

Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial

Rhythm Biosciences Betters ColoSTAT Results

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

New 90-day high: AU$1.64

Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site

New 90-day high: AU$1.56

Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites

New 90-day high: AU$1.38

New 90-day high: AU$0.88

Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

New 90-day high: AU$0.28

New 90-day high: AU$0.21

Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial

New 90-day high - AU$0.20

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million.

Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Discover strong dividend paying companies